JP2024506291A5 - - Google Patents

Info

Publication number
JP2024506291A5
JP2024506291A5 JP2023547188A JP2023547188A JP2024506291A5 JP 2024506291 A5 JP2024506291 A5 JP 2024506291A5 JP 2023547188 A JP2023547188 A JP 2023547188A JP 2023547188 A JP2023547188 A JP 2023547188A JP 2024506291 A5 JP2024506291 A5 JP 2024506291A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
acid
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015098 external-priority patent/WO2022169962A1/en
Publication of JP2024506291A publication Critical patent/JP2024506291A/ja
Publication of JP2024506291A5 publication Critical patent/JP2024506291A5/ja
Pending legal-status Critical Current

Links

JP2023547188A 2021-02-03 2022-02-03 吸入用のフューリンインヒビターの製剤 Pending JP2024506291A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145363P 2021-02-03 2021-02-03
US63/145,363 2021-02-03
PCT/US2022/015098 WO2022169962A1 (en) 2021-02-03 2022-02-03 Formulation of furin inhibitor for inhalation

Publications (2)

Publication Number Publication Date
JP2024506291A JP2024506291A (ja) 2024-02-13
JP2024506291A5 true JP2024506291A5 (cg-RX-API-DMAC7.html) 2025-02-06

Family

ID=80446118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547188A Pending JP2024506291A (ja) 2021-02-03 2022-02-03 吸入用のフューリンインヒビターの製剤

Country Status (9)

Country Link
US (1) US20240307374A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506291A (cg-RX-API-DMAC7.html)
KR (1) KR20230142752A (cg-RX-API-DMAC7.html)
CN (1) CN117222410A (cg-RX-API-DMAC7.html)
AU (1) AU2022215580A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205921A1 (cg-RX-API-DMAC7.html)
IL (1) IL304858A (cg-RX-API-DMAC7.html)
WO (1) WO2022169962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
ES2739352T3 (es) * 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
ES2774249T3 (es) * 2014-02-14 2020-07-20 Respivert Ltd Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors

Similar Documents

Publication Publication Date Title
JP5286251B2 (ja) インフルエンザ治療剤
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2016534063A5 (cg-RX-API-DMAC7.html)
KR20080005601A (ko) Pde4 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합
JP2019528320A5 (cg-RX-API-DMAC7.html)
JP2023110019A5 (cg-RX-API-DMAC7.html)
EA004657B1 (ru) Фармацевтическая композиция на основе обладающих антихолинергическим действием соединений , способ ее получения и применение
JP2024170583A5 (cg-RX-API-DMAC7.html)
JP2009537246A5 (cg-RX-API-DMAC7.html)
RU2005100781A (ru) Комбинация азеластина и стероидов
HRP20171044T1 (hr) Kemijski i metabolički stabilni dipeptid s potentnom aktivnošću blokatora natrijevog kanala
JP2022527401A5 (cg-RX-API-DMAC7.html)
US20190023707A1 (en) Composition
JP2024544538A5 (cg-RX-API-DMAC7.html)
ES2576980T3 (es) Derivados químicos de jasmonato, composiciones farmacéuticas y métodos de uso de los mismos
WO2014158119A1 (en) Aqueous solution composition containing ipratropium and oxymetazoline
JP2022527630A5 (cg-RX-API-DMAC7.html)
WO2005113492A1 (fr) Sels d'ambroxol analogues de cysteine, procedes d'elaboration et utilisations
JP2007519701A5 (cg-RX-API-DMAC7.html)
JP2025507962A5 (cg-RX-API-DMAC7.html)
JP2008520611A5 (cg-RX-API-DMAC7.html)
JP2007531743A (ja) 他の薬剤と組合せた(r,r)−ホルモテロール
JP2023521554A (ja) 抗ウイルス治療
JP2009526817A5 (cg-RX-API-DMAC7.html)
JP2010518160A5 (cg-RX-API-DMAC7.html)